Exhibit 99.1

FOR IMMEDIATE RELEASE


IT&E International Group Announces New Trading Symbol

SAN JOSE, CA - June 23, 2004 - IT&E International Group (OTC BB: ITER)
announced today that the company has been awarded a new trading symbol and
is now trading under the ticker ITER.  Formerly private IT&E was combined
with Clinical Trials Assistance Corporation, a public corporation earlier
this year.  The resulting advance clinical research studies and regulatory
compliance company officially changed its name to IT&E International Group.

IT&E focuses on providing leading pharmaceutical, biotech, healthcare and
other life science companies with project-based consulting services in the
areas of data management, clinical programming, biostatistics and clinical
validation.  The company, with its talented team of industry veterans with
many years of biopharma experience, utilizes the latest tools and procedures
to help its clients move quickly and effectively through the FDA approval
process.  Its services range from providing patients for drug trials, skilled
personnel for trials, enterprise software and training to manage data and
ensure FDA compliance and validation of new pharmaceutical manufacturing
facilities to biostatistics support and analysis, audits, contract research
services, data entry and verification services and providing total clinical
solutions that take companies completely through Phase IV clinical trials.
IT&E is also one of only a few companies worldwide that has successfully led
a National Institute of Health audit for a client.

Included in this release are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended.  Although the Company
believes that the expectations reflected in such forward-looking statements
are reasonable, it can give no assurance that such expectations reflected in
such forward-looking statements will prove to have been correct.  The
Company's actual results could differ materially from those anticipated in
the forward-looking statements.


CONTACT:
Peter R. Sollenne, CEO
408-938-1000